Phase 2 N=40 Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Multiple Myeloma
Primary: 4 Cycle Response Rate — 0.971 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=123 Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
N/A N=16 Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
Multiple Myeloma · Myeloma · Disability Physical
Primary: Intervention Attendance (Feasibility) — 50 percentage of participants
Phase 2 N=53 Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment — 28; 16 participants
Phase 2 N=38 Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Progression-free Survival (PFS) Rate at 12 Months — 79 percentage of participants
Phase 2 N=63 Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of…
Phase 2 N=74 Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Combination Therapy With VELCADE, Dexamethasone, and Doxil, (RVDD) — 25; 1.3; 20; 30 mg
Phase 2 N=57 Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
Multiple Myeloma
Primary: Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen — 77.2 percentage of participants
Phase 2 N=35 Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multiple Myeloma
Primary: The Maximum Tolerated Dose (MTD) of Carfilzomib — 36 mg/m^2
Phase 2 N=20 Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Phase 2 N=148 Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants — 27; 24 percentage of participants — p=0.4859
Phase 2 N=50 Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants at Each Response Category (Stable Disease, Minimal Response, Partial Response, Very Good Partial Response, Near Complete Response/Complete…
Phase 2 N=80 Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Plasma Cell Myeloma
Primary: Proportion of Patients Who Achieve a Confirmed Complete Response (CR) — 0.32; 0.30 proportion of participants
Phase 2 N=26 Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Patients With Overall Confirmed Response — 3; 5; 10 participants
Phase 2 N=66 Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Multiple Myeloma
Primary: Objective Response (OR) Rate — 0.41 proportion of participants
Phase 2 N=25 A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
Multiple Myeloma
Primary: Overall Response Rate — 95 percentage of participants
Phase 2 N=18 A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002
Phase 2 N=55 Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Phase 2 N=64 Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: Maximum Tolerated Dose (Phase I) — 0; 0; 0; 3 participants
Phase 2 N=24 Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Stage I Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Count of Participants That Experience Overall Response Following 4 Cycles of the Combination Regimen BBd — 13 Participants
Phase 2 N=60 Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 2 N=11 Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
Plasma Cell Myeloma
Primary: Proportion of Complete Response Plus Very Good Partial Response (VGPR) — 0 proportion of participants
Phase 2 N=31 Imaging in MGUS, SMM and MM
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Phase 2 N=61 Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Ixazomib (Phase 1) — 3; 4; 3; 4 mg
Phase 2 N=52 Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Multiple Myeloma
Primary: Induction Feasibility Rate (IFR) — 33 Participants
Phase 2 N=45 Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Multiple Myeloma
Primary: Number of Participants With Serious and Non-serious Adverse Events — 45 Participants
Phase 2 N=44 Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma
Stage I Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Response Rate on Induction — 47.6 percentage of participants
Phase 2 N=46 Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Overall Response Rate (Complete and Partial) — 77.50 percentage of participants
Phase 2 N=30 Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
Multiple Myeloma
Primary: Clinical Response to Treatment — 81.5 percentage of participants
Phase 2 N=46 Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: 4-Cycle Induction Overall Response Rate (ORR) — 95 percentage of participants